Princeton, United States
CytoSorbents Corporation is a New Jersey-based company that focuses on the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. The company is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery through blood purification. Its flagship product, CytoSorb®, has gained distribution in more than 70 countries and holds CE Mark approval in the EU for cytokine, bilirubin, and myoglobin removal in critical care applications. Additionally, it is approved for the removal of ticagrelor and rivaroxaban during cardiothoracic surgery.
Having been founded in 1997, CytoSorbents has been making significant strides in the Biotechnology, Health and Wellness, and Pharmaceutical industries. The company is currently engaged in multiple active clinical trials, including pivotal randomized, controlled trials in the United States aimed at supporting FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.
The most recent investment in CytoSorbents Corporation came in the form of a $15.00M Post-IPO Debt investment on 02 July 2024. The investment was made by Avenue Capital.
CytoSorbents' dedication to developing innovative solutions for critical care and its success in securing significant investments make it a company to watch in the evolving landscape of medical technology.
